{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:14:13Z","timestamp":1787170453609,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute, NIH","doi-asserted-by":"crossref","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"crossref","award":["MOA 393-12 SC"],"award-info":[{"award-number":["MOA 393-12 SC"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,2]]},"DOI":"10.1093\/cid\/ciy082","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T15:10:19Z","timestamp":1517497819000},"page":"193-201","source":"Crossref","is-referenced-by-count":55,"title":["Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug\u2013Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine"],"prefix":"10.1093","volume":"67","author":[{"given":"Kristina M","family":"Brooks","sequence":"first","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, Clinical Center, National Institutes of Health (NIH), Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jomy M","family":"George","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, Clinical Center, National Institutes of Health (NIH), Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice K","family":"Pau","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rupert","sequence":"additional","affiliation":[{"name":"AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mehaffy","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithwiraj","family":"De","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M","family":"Dobos","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anela","family":"Kellogg","sequence":"additional","affiliation":[{"name":"Clinical Monitoring Research Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Clinical Research Section, NIAID, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryellen","family":"McManus","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center, NIH, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul M","family":"Alfaro","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, Clinical Center, National Institutes of Health (NIH), Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Hadigan","sequence":"additional","affiliation":[{"name":"Clinical Research Section, NIAID, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center, NIH, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Kumar","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Unit, Pharmacy Department, Clinical Center, National Institutes of Health (NIH), Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,3]]},"reference":[{"key":"key\n\t\t\t\t20180702005814_CIT0001","volume-title":"Global tuberculosis report 2015","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20180702005814_CIT0002","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180702005814_CIT0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180702005814_CIT0004","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis infection in HIV co-infected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180702005814_CIT0005","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent Mycobacterium tuberculosis infection [manuscript published online ahead of print 30 May 2017]","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0006","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180702005814_CIT0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180702005814_CIT0009","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180702005814_CIT0011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA Panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180702005814_CIT0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180702005814_CIT0013","article-title":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at"},{"key":"key\n\t\t\t\t20180702005814_CIT0014","first-page":"703","article-title":"Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids","volume":"3","author":"Peloquin","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0015","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1128\/AAC.00554-08","article-title":"Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations","volume":"52","author":"Dooley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180702005814_CIT0016","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180702005814_CIT0017","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180702005814_CIT0018","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0019","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jama.1977.03280170053030","article-title":"Spiking fever from isoniazid simulating a septic process","volume":"238","author":"Jacobs","year":"1977","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180702005814_CIT0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0970-2113.106176","article-title":"Isoniazid-induced flu-like syndrome: a rare side effect","volume":"30","author":"Pandit","year":"2013","journal-title":"Lung India"},{"key":"key\n\t\t\t\t20180702005814_CIT0021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0022","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00000421-198812000-00013","article-title":"Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders","volume":"11","author":"Creagan","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"key\n\t\t\t\t20180702005814_CIT0023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/15476910903501748","article-title":"Cytokine and autoantibody patterns in acute liver failure","volume":"7","author":"Li","year":"2010","journal-title":"J Immunotoxicol"},{"key":"key\n\t\t\t\t20180702005814_CIT0024","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1086\/315155","article-title":"Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis","volume":"180","author":"Lauw","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180702005814_CIT0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180702005814_CIT0026","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjd.14839","article-title":"Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome","volume":"176","author":"Ye","year":"2017","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t20180702005814_CIT0027","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/toxsci\/kfx069","article-title":"Characterization of drug-specific signaling between primary human hepatocytes and immune cells","volume":"158","author":"Ogese","year":"2017","journal-title":"Toxicol Sci"},{"key":"key\n\t\t\t\t20180702005814_CIT0028","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26564","article-title":"Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure","volume":"59","author":"Metushi","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180702005814_CIT0029","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/15376516.2015.1033074","article-title":"The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid\/rifampicin-induced hepatotoxicity","volume":"25","author":"Guo","year":"2015","journal-title":"Toxicol Mech Methods"},{"key":"key\n\t\t\t\t20180702005814_CIT0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1310\/hct1505-199","article-title":"Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients","volume":"15","author":"Curtis","year":"2014","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180702005814_CIT0031","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/AAC.01749-09","article-title":"Pharmacokinetics of darunavir\/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers","volume":"54","author":"Sekar","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180702005814_CIT0032","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1753-5174.2009.00017.x","article-title":"Unexpected hepatotoxicity of rifampin and saquinavir\/ritonavir in healthy male volunteers","volume":"2","author":"Schmitt","year":"2009","journal-title":"Arch Drug Inf"},{"key":"key\n\t\t\t\t20180702005814_CIT0033","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180702005814_CIT0034","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/jac\/dkl552","article-title":"Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis","volume":"59","author":"Ribera","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180702005814_CIT0035","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/135965350400900606","article-title":"The use of saquinavir\/ritonavir 1000\/100 mg twice daily in patients with tuberculosis receiving rifampin","volume":"9","author":"Losso","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180702005814_CIT0036","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/clpt.2010.355","article-title":"A fresh look at the mechanism of isoniazid-induced hepatotoxicity","volume":"89","author":"Metushi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180702005814_CIT0037","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1128\/AAC.03282-14","article-title":"Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects","volume":"58","author":"Song","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180702005814_CIT0038","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1248\/bpb.b15-00313","article-title":"Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes","volume":"38","author":"Shimokawa","year":"2015","journal-title":"Biol Pharm Bull"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/2\/193\/25103169\/ciy082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T15:41:09Z","timestamp":1660405269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/2\/193\/4836314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,3]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,3]]},"published-print":{"date-parts":[[2018,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy082","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,15]]},"published":{"date-parts":[[2018,2,3]]}}}